Trial · NCT01969838
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Splenic Response Rate at Week 24 | Momelotinib (MMB) | Responder | 57 | Participants | |
| Splenic Response Rate at Week 24 | Ruxolitinib (RUX) | Responder | 64 | Participants | |
| Splenic Response Rate at Week 24 | Momelotinib (MMB) | Nonresponder | 158 | Participants | |
| Splenic Response Rate at Week 24 | Ruxolitinib (RUX) | Nonresponder | 153 | Participants | |
| Total Symptom Score (TSS) Response Rate at Week 24 | Momelotinib (MMB) | Responder | 60 | Participants | |
| Total Symptom Score (TSS) Response Rate at Week 24 | Ruxolitinib (RUX) | Responder | 89 | Participants | |
| Total Symptom Score (TSS) Response Rate at Week 24 | Momelotinib (MMB) | Nonresponder | 151 | Participants | |
| Total Symptom Score (TSS) Response Rate at Week 24 | Ruxolitinib (RUX) | Nonresponder | 122 | Participants | |
| Rate of Red Blood Cell (RBC) Transfusions in the Double-blind Phase, (the Average Number of RBC Units Transfused Per Month Not Associated With Overt Bleeding) | Momelotinib (MMB) | 0.0 | Inter-Quartile Range 0.0 to 0.2 | units/month | |
| Rate of Red Blood Cell (RBC) Transfusions in the Double-blind Phase, (the Average Number of RBC Units Transfused Per Month Not Associated With Overt Bleeding) | Ruxolitinib (RUX) | 0.4 | Inter-Quartile Range 0.0 to 1.5 | units/month | |
RBC Transfusion Independence Rate at Week 24, (Defined as Absence of RBC Transfusions and no Hemoglobin Level Below 8 g/dL in the 12 Weeks Prior to Week 24, Excluding Cases Associated With Clinically Overt Bleeding) | Momelotinib (MMB) | Responder | 143 | Participants | |
RBC Transfusion Independence Rate at Week 24, (Defined as Absence of RBC Transfusions and no Hemoglobin Level Below 8 g/dL in the 12 Weeks Prior to Week 24, Excluding Cases Associated With Clinically Overt Bleeding) | Ruxolitinib (RUX) | Responder | 107 | Participants | |
RBC Transfusion Independence Rate at Week 24, (Defined as Absence of RBC Transfusions and no Hemoglobin Level Below 8 g/dL in the 12 Weeks Prior to Week 24, Excluding Cases Associated With Clinically Overt Bleeding) | Momelotinib (MMB) | Nonresponder | 72 | Participants | |
RBC Transfusion Independence Rate at Week 24, (Defined as Absence of RBC Transfusions and no Hemoglobin Level Below 8 g/dL in the 12 Weeks Prior to Week 24, Excluding Cases Associated With Clinically Overt Bleeding) | Ruxolitinib (RUX) | Nonresponder | 110 | Participants | |
RBC Transfusion Dependence Rate at Week 24. (Defined as Having Had at Least 4 Units of RBC Transfusions, or a Hemoglobin Level Below 8 g/dL in 8 Weeks Prior to Week 24 (Excluding Cases Associated With Clinically Overt Bleeding)). | Momelotinib (MMB) | Dependent | 65 | Participants | |
RBC Transfusion Dependence Rate at Week 24. (Defined as Having Had at Least 4 Units of RBC Transfusions, or a Hemoglobin Level Below 8 g/dL in 8 Weeks Prior to Week 24 (Excluding Cases Associated With Clinically Overt Bleeding)). | Ruxolitinib (RUX) | Dependent | 87 | Participants | |
RBC Transfusion Dependence Rate at Week 24. (Defined as Having Had at Least 4 Units of RBC Transfusions, or a Hemoglobin Level Below 8 g/dL in 8 Weeks Prior to Week 24 (Excluding Cases Associated With Clinically Overt Bleeding)). | Momelotinib (MMB) | Nondependent | 150 | Participants | |
RBC Transfusion Dependence Rate at Week 24. (Defined as Having Had at Least 4 Units of RBC Transfusions, or a Hemoglobin Level Below 8 g/dL in 8 Weeks Prior to Week 24 (Excluding Cases Associated With Clinically Overt Bleeding)). | Ruxolitinib (RUX) | Nondependent | 130 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01969838/results